Review Article | Published:

Nonantibiotic prevention and management of recurrent urinary tract infection


Urinary tract infections (UTIs) are highly prevalent, lead to considerable patient morbidity, incur large financial costs to health-care systems and are one of the most common reasons for antibiotic use worldwide. The growing problem of antimicrobial resistance means that the search for nonantibiotic alternatives for the treatment and prevention of UTI is of critical importance. Potential nonantibiotic measures and treatments for UTIs include behavioural changes, dietary supplementation (such as Chinese herbal medicines and cranberry products), NSAIDs, probiotics, d-mannose, methenamine hippurate, estrogens, intravesical glycosaminoglycans, immunostimulants, vaccines and inoculation with less-pathogenic bacteria. Some of the results of trials of these approaches are promising; however, high-level evidence is required before firm recommendations for their use can be made. A combination of these agents might provide the optimal treatment to reduce recurrent UTI, and trials in specific population groups are required.

Key points

  • Rising rates of antimicrobial resistance, fuelled by the overuse of antibiotics in humans, are a serious threat to global public health.

  • Alternatives to antibiotics for the prevention of recurrent urinary tract infection (UTI) are attractive options to reduce the risks of antimicrobial resistance.

  • The most commonly studied nonantibiotic management options for recurrent UTI include cranberries, probiotics, d-mannose, methenamine hippurate, estrogens, intravesical glycosaminoglycans and immunostimulants.

  • Studies of novel vaccines targeting the adherence mechanisms of uropathogenic bacteria seem promising, but human trials are required to determine the efficacy of this approach.

  • Evidence for the nonantibiotic measures is hampered by considerable heterogeneity, and further placebo-controlled randomized trials of these agents are needed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Stamm, W. E. & Norrby, S. R. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 183, S1–S4 (2001).

  2. 2.

    Laupland, K. B., Ross, T., Pitout, J. D., Church, D. L. & Gregson, D. B. Community-onset urinary tract infections: a population-based assessment. Infection 35, 150–153 (2007).

  3. 3.

    Mabeck, C. E. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad. Med. J. 48, 69–75 (1972).

  4. 4.

    Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113 (Suppl 1A), 5s–13s (2002).

  5. 5.

    Nicolle, L. E. Urinary tract infection. Crit. Care Clin. 29, 699–715 (2013).

  6. 6.

    Loveday, H. P. et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J. Hosp. Infect. 86, S1–S70 (2014).

  7. 7.

    Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).

  8. 8.

    Ellis, A. K. & Verma, S. Quality of life in women with urinary tract infections: is benign disease a misnomer? J. Am. Board Fam. Pract. 13, 392–397 (2000).

  9. 9.

    Foxman, B. & Frerichs, R. R. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am. J. Publ. Health 75, 1308–1313 (1985).

  10. 10.

    Akkerman, A. E., Kuyvenhoven, M. M., Verheij, T. J. & van Dijk, L. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiol. Drug Saf. 17, 378–383 (2008).

  11. 11.

    European Centre for Disease Prevention and Control. ECDC/EMEA Joint Technical Report. The bacterial challenge: time to react (ECDC, 2009).

  12. 12.

    Llor, C. & Bjerrum, L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. Drug Safety 5, 229–241 (2014).

  13. 13.

    Gupta, K. et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J. Infect. Dis. 178, 446–450 (1998).

  14. 14.

    Foxman, B. et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am. J. Epidemiol. 156, 1133–1140 (2002).

  15. 15.

    Mulvey, M. A., Schilling, J. D. & Hultgren, S. J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69, 4572–4579 (2001).

  16. 16.

    Schilling, J. D., Lorenz, R. G. & Hultgren, S. J. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic. Escherichia coli. Infect. Immun. 70, 7042–7049 (2002).

  17. 17.

    Rosen, D. A., Hooton, T. M., Stamm, W. E., Humphrey, P. A. & Hultgren, S. J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 4, e329 (2007).

  18. 18.

    World Health Organisation. Antimicrobial resistance: global report on surveillance 2014 (WHO, 2014).

  19. 19.

    Bryce, A. et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 352, i939 (2016).

  20. 20.

    Johnson, J. R., Johnston, B., Clabots, C., Kuskowski, M. A. & Castanheira, M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51, 286–294 (2010).

  21. 21.

    Wang, Y. et al. Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infect. Dis. 17, 390–399 (2017).

  22. 22.

    Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2015).

  23. 23.

    Van Boeckel, T. P. et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14, 742–750 (2014).

  24. 24.

    Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance. Microbiol. Spectr. (2016).

  25. 25.

    Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. 1940. Rev. Infect. Dis. 10, 677–678 (1988).

  26. 26.

    Logan, L. K. & Weinstein, R. A. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J. Infect. Dis. 215, S28–S36 (2017).

  27. 27.

    Tangden, T., Adler, M., Cars, O., Sandegren, L. & Lowdin, E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J. Antimicrob. Chemother. 68, 1319–1326 (2013).

  28. 28.

    Adler, M., Anjum, M., Andersson, D. I. & Sandegren, L. Influence of acquired β-lactamases on the evolution of spontaneous carbapenem resistance in. Escherichia coli. J. Antimicrob. Chemother. 68, 51–59 (2013).

  29. 29.

    Ma, L. et al. Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 53, 104–111 (2009).

  30. 30.

    Sanchez, G. V., Baird, A. M., Karlowsky, J. A., Master, R. N. & Bordon, J. M. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J. Antimicrob. Chemother. 69, 3259–3262 (2014).

  31. 31.

    Russell, G. Antibiotic resistance in children with E coli urinary tract infection. BMJ 352, i1399 (2016).

  32. 32.

    Heinemann, C. & Reid, G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can. J. Microbiol. 51, 777–781 (2005).

  33. 33.

    Falagas, M. E., Rafailidis, P. I. & Makris, G. C. Bacterial interference for the prevention and treatment of infections. Int. J. Antimicrob. Agents 31, 518–522 (2008).

  34. 34.

    Chan, R. C., Reid, G., Irvin, R. T., Bruce, A. W. & Costerton, J. W. Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect. Immun. 47, 84–89 (1985).

  35. 35.

    Hooton, T. M. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 335, 468–474 (1996).

  36. 36.

    Hooton, T. M., Roberts, P. L. & Stamm, W. E. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin. Infect. Dis. 19, 274–278 (1994).

  37. 37.

    Xie, J., Foxman, B., Zhang, L. & Marrs, C. F. Molecular epidemiologic identification of Escherichia coli genes that are potentially involved in movement of the organism from the intestinal tract to the vagina and bladder. J. Clin. Microbiol. 44, 2434–2441 (2006).

  38. 38.

    Scholes, D. et al. Risk factors for recurrent urinary tract infection in young women. J. Infect. Dis. 182, 1177–1182 (2000).

  39. 39.

    Moore, E. E. et al. Sexual intercourse and risk of symptomatic urinary tract infection in post-menopausal women. J. Gen. Intern. Med. 23, 595–599 (2008).

  40. 40.

    Foxman, B. et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J. Clin. Epidemiol. 54, 710–718 (2001).

  41. 41.

    Raz, R. et al. Recurrent urinary tract infections in postmenopausal women. Clin. Infect. Dis. 30, 152–156 (2000).

  42. 42.

    Lema, V. M. Urinary tract infection in young healthy women following heterosexual anal intercourse: case reports. Afr. J. Reproductive Health 19, 134–139 (2015).

  43. 43.

    Coull, N., Mastoroudes, H., Popert, R. & O’Brien, T. S. Redefining urological history taking - anal intercourse as the cause of unexplained symptoms in heterosexuals. Ann. R. Coll. Surg. Engl. 90, 403–405 (2008).

  44. 44.

    Gupta, K., Hillier, S. L., Hooton, T. M., Roberts, P. L. & Stamm, W. E. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J. Infect. Dis. 181, 595–601 (2000).

  45. 45.

    Handley, M. A., Reingold, A. L., Shiboski, S. & Padian, N. S. Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. Epidemiology 13, 431–436 (2002).

  46. 46.

    Su, S. B., Wang, J. N., Lu, C. W. & Guo, H. R. Reducing urinary tract infections among female clean room workers. J. Womens Health 15, 870–876 (2006).

  47. 47.

    Foxman, B. & Chi, J. W. Health behavior and urinary tract infection in college-aged women. J. Clin. Epidemiol. 43, 329–337 (1990).

  48. 48.

    Adatto, K., Doebele, K. G., Galland, L. & Granowetter, L. Behavioral factors and urinary tract infection. JAMA 241, 2525–2526 (1979).

  49. 49.

    Nygaard, I. & Linder, M. Thirst at work — an occupational hazard? Int. Urogynecol. J. Pelvic Floor Dysfunct. 8, 340–343 (1997).

  50. 50.

    Eckford, S. D., Keane, D. P., Lamond, E., Jackson, S. R. & Abrams, P. Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women. Br. J. Urol. 76, 90–93 (1995).

  51. 51.

    Murphy, F. J., Zelman, S. & Mau, W. Ascorbic acid as a urinary acidifying agent. 2. Its adjunctive role in chronic urinary infection. J. Urol. 94, 300–303 (1965).

  52. 52.

    McDonald, D. F. & Murphy, G. P. Bacteriostatic and acidifying effects of methionine, hydrolyzed casein, and AA on the urine. N. Engl. J. Med. 261, 803–805 (1959).

  53. 53.

    Castello, T., Girona, L., Gomez, M. R., Mena Mur, A. & Garcia, L. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord 34, 592–593 (1996).

  54. 54.

    Peng, M. M., Fang, Y., Hu, W. & Huang, Q. The pharmacological activities of compound salvia plebeia granules on treating urinary tract infection. J. Ethnopharmacol. 129, 59–63 (2010).

  55. 55.

    Yan, D., Jin, C., Xiao, X. H. & Dong, X. P. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry. J. Biochem. Biophys. Methods 70, 845–849 (2008).

  56. 56.

    Flower, A., Wang, L. Q., Lewith, G., Liu, J. P. & Li, Q. Chinese herbal medicine for treating recurrent urinary tract infections in women. Cochrane Database Syst Rev. 6, CD01044 (2015).

  57. 57.

    Ma, X. Y., Zhi, Y., Zhang, X., Zhao, H. & Gao, G. J. Clinical study of Xianqing Houbu method in treating senile female recurrent urinary tract infection. J. Emergency Tradit. Chinese Med. 20, 1918–1919 (2011).

  58. 58.

    Shen, Y. & Yao, Q. Clinical observation of “baitouweng decoction” and “erxian decoction” in treating lower urinary infection in 52 postmenopausal women. Shanghai J. Tradit. Chinese Med. 41, 37–38 (2007).

  59. 59.

    Zhao, K. S. et al. Clinical study of clearing liver fire, removing dampness, strengthening spleen and tonifying kidney methods in treating middle-aged and old woman with chronic urinary tract infection. Int. J. Tradit. Chinese Med. 33, 976–978 (2011).

  60. 60.

    Chen, M., Wang, Y. & Gu, X. C. Clinical observation of modified “erxian decoction” plus antibiotics in treating chronic urinary tract infection in middle-aged and old women. Shanghai J. Tradit. Chinese Med. 42, 48–49 (2008).

  61. 61.

    Luo, M. Clinical study of bushen tonglin decoction on female with chronic urinary tract infection. Hubei Uni. Chinese Med. (2011).

  62. 62.

    Gu, X. C., Xu, Z., Chen, M. & Wang, M. Study of erding erxian docoction compared with sanjin tablet in treating recurrent urinary tract infection. Chinese J. Integr. Tradit. Western Nephrol. 12, 623–624 (2011).

  63. 63.

    Qin, S. G. Clinical analysis of Ningmitai capsule on 60 cases chronic urinary tract infection. Hebei Med. 10, 700–702 (2004).

  64. 64.

    Balshem, H. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64, 401–406 (2011).

  65. 65.

    Guay, D. R. Cranberry and urinary tract infections. Drugs 69, 775–807 (2009).

  66. 66.

    Borukh, I. F., Kirbaba, V. I. & Senchuk, G. V. [Antimicrobial properties of cranberry]. Voprosy Pitaniia 31, 82 (1972).

  67. 67.

    Hisano, M., Bruschini, H., Nicodemo, A. C. & Srougi, M. Cranberries and lower urinary tract infection prevention. Clinics 67, 661–668 (2012).

  68. 68.

    Lynch, D. M. Cranberry for prevention of urinary tract infections. Am. Fam. Physician 70, 2175–2177 (2004).

  69. 69.

    Beachey, E. H. Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface. J. Infect. Dis. 143, 325–345 (1981).

  70. 70.

    Howell, A. B. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol. Nutr. Food Res. 51, 732–737 (2007).

  71. 71.

    Ofek, I. & Beachey, E. H. Mannose binding and epithelial cell adherence of Escherichia coli. Infect. Immun. 22, 247–254 (1978).

  72. 72.

    Zafriri, D., Ofek, I., Adar, R., Pocino, M. & Sharon, N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob. Agents Chemother. 33, 92–98 (1989).

  73. 73.

    Hidalgo, G., Chan, M. & Tufenkji, N. Inhibition of Escherichia coli CFT073 fliC expression and motility by cranberry materials. Appl. Environ. Microbiol. 77, 6852–6857 (2011).

  74. 74.

    O’May, C. & Tufenkji, N. The swarming motility of Pseudomonas aeruginosa is blocked by cranberry proanthocyanidins and other tannin-containing materials. Appl. Environ. Microbiol. 77, 3061–3067 (2011).

  75. 75.

    Howell, A. B. et al. A-Type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 66, 2281–2291 (2005).

  76. 76.

    Liu, Y., Black, M. A., Caron, L. & Camesano, T. A. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Biotechnol. Bioengineer. 93, 297–305 (2006).

  77. 77.

    Vasileiou, I., Katsargyris, A., Theocharis, S. & Giaginis, C. Current clinical status on the preventive effects of cranberry consumption against urinary tract infections. Nutr. Res. 33, 595–607 (2013).

  78. 78.

    Ren, D. et al. Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Appl. Environ. Microbiol. 71, 4022–4034 (2005).

  79. 79.

    Grace, M. H., Massey, A. R., Mbeunkui, F., Yousef, G. G. & Lila, M. A. Comparison of health-relevant flavonoids in commonly consumed cranberry products. J. Food Sci. 77, H176–H183 (2012).

  80. 80.

    Howell, A. B. & Foxman, B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. JAMA 287, 3082–3083 (2002).

  81. 81.

    Avorn, J. et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 271, 751–754 (1994).

  82. 82.

    Howell, A. B. et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect. Dis. 10, 94 (2010).

  83. 83.

    Beerepoot, M. & Geerlings, S. Non-antibiotic prophylaxis for urinary tract infections. Pathogens 5, E36 (2016).

  84. 84.

    Luis, A., Domingues, F. & Pereira, L. Can cranberries contribute to reduce the incidence of urinary tract infections? A systematic review with meta-analysis and trial sequential analysis of clinical trials. J. Urol. 198, 614–621 (2017).

  85. 85.

    Jepson, R. G., Williams, G. & Craig, J. C. Cranberries for preventing urinary tract infections. Cochrane Database Syst. Rev. 10, CD001321 (2012).

  86. 86.

    Wang, C. H. et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch. Intern. Med. 172, 988–996 (2012).

  87. 87.

    Stothers, L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can. J. Urol. 9, 1558–1562 (2002).

  88. 88.

    Vostalova, J. et al. Are high proanthocyanidins key to cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother. Res. 29, 1559–1567 (2015).

  89. 89.

    Maki, K. C. et al. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection. Am. J. Clin. Nutr. 103, 1434–1442 (2016).

  90. 90.

    Kontiokari, T. et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322, 1571 (2001).

  91. 91.

    Stapleton, A. E. et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin. Proc. 87, 143–150 (2012).

  92. 92.

    Barbosa-Cesnik, C. et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin. Infect. Dis. 52, 23–30 (2011).

  93. 93.

    Foxman, B. et al. Risk factors for second urinary tract infection among college women. Am. J. Epidemiol. 151, 1194–1205 (2000).

  94. 94.

    McMurdo, M. E., Argo, I., Phillips, G., Daly, F. & Davey, P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. J. Antimicrob. Chemother. 63, 389–395 (2009).

  95. 95.

    Beerepoot, M. A. et al. Cranberries versus antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch. Intern. Med. 171, 1270–1278 (2011).

  96. 96.

    Beerepoot, M. A., Geerlings, S. E., van Haarst, E. P., van Charante, N. M. & ter Riet, G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J. Urol. 190, 1981–1989 (2013).

  97. 97.

    Caljouw, M. A. et al. Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities. J. Am. Geriatr. Soc. 62, 103–110 (2014).

  98. 98.

    Juthani-Mehta, M. et al. Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial. JAMA 316, 1879–1887 (2016).

  99. 99.

    Afshar, K., Stothers, L., Scott, H. & MacNeily, A. E. Cranberry juice for the prevention of pediatric urinary tract infection: a randomized controlled trial. J. Urol. 188, 1584–1587 (2012).

  100. 100.

    Ferrara, P. et al. Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children. Scand. J. Urol. Nephrol. 43, 369–372 (2009).

  101. 101.

    Wing, D. A., Rumney, P. J., Preslicka, C. W. & Chung, J. H. Daily cranberry juice for the prevention of asymptomatic bacteriuria in pregnancy: a randomized, controlled pilot study. J. Urol. 180, 1367–1372 (2008).

  102. 102.

    Dugoua, J. J., Seely, D., Perri, D., Mills, E. & Koren, G. Safety and efficacy of cranberry (Vaccinium macrocarpon) during pregnancy and lactation. Can. J. Clin. Pharmacol. 15, e80–e86 (2008).

  103. 103.

    Hannan, T. J., Mysorekar, I. U., Hung, C. S., Isaacson-Schmid, M. L. & Hultgren, S. J. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 6, e1001042 (2010).

  104. 104.

    Schlager, T. A., LeGallo, R., Innes, D., Hendley, J. O. & Peters, C. A. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J. Urol. 186, 2359–2364 (2011).

  105. 105.

    Hannan, T. J. et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine 1, 46–57 (2014).

  106. 106.

    Wheeler, M. A., Hausladen, D. A., Yoon, J. H. & Weiss, R. M. Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J. Urol. 168, 1568–1573 (2002).

  107. 107.

    Bleidorn, J., Gagyor, I., Kochen, M. M., Wegscheider, K. & Hummers-Pradier, E. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?—results of a randomized controlled pilot trial. BMC Med. 8, 30 (2010).

  108. 108.

    Gagyor, I. et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 351, h6544 (2015).

  109. 109.

    Ferry, S. A., Holm, S. E., Stenlund, H., Lundholm, R. & Monsen, T. J. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand. J. Infect. Dis. 36, 296–301 (2004).

  110. 110.

    Christiaens, T. C. et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br. J. Gen. Pract. 52, 729–734 (2002).

  111. 111.

    Kalle, A. M. & Rizvi, A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob. Agents Chemother. 55, 439–442 (2011).

  112. 112.

    Velraeds, M. M., van der Mei, H. C., Reid, G. & Busscher, H. J. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl. Environ. Microbiol. 62, 1958–1963 (1996).

  113. 113.

    Bruce, A. W., Chadwick, P., Hassan, A. & VanCott, G. F. Recurrent urethritis in women. Can. Med. Assoc. J. 108, 973–976 (1973).

  114. 114.

    Reid, G., Bruce, A. W., Cook, R. L. & Llano, M. Effect on urogenital flora of antibiotic therapy for urinary tract infection. Scand. J. Infect. Dis. 22, 43–47 (1990).

  115. 115.

    Andreu, A., Stapleton, A. E., Fennell, C. L., Hillier, S. L. & Stamm, W. E. Hemagglutination, adherence, and surface properties of vaginal Lactobacillus species. J. Infect. Dis. 171, 1237–1243 (1995).

  116. 116.

    Osset, J., Bartolome, R. M., Garcia, E. & Andreu, A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J. Infect. Dis. 183, 485–491 (2001).

  117. 117.

    Mastromarino, P. et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J. Appl. Microbiol. 93, 884–893 (2002).

  118. 118.

    Barrons, R. & Tassone, D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin. Ther. 30, 453–468 (2008).

  119. 119.

    Zarate, G. & Nader-Macias, M. E. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. Lett. Appl. Microbiol. 43, 174–180 (2006).

  120. 120.

    de Llano, D. G. et al. Strain-specific inhibition of the adherence of uropathogenic bacteria to bladder cells by probiotic Lactobacillus spp. Pathog. Dis. (2017).

  121. 121.

    Manzoor, A., Ul-Haq, I., Baig, S., Qazi, J. I. & Seratlic, S. Efficacy of locally isolated lactic acid bacteria against antibiotic-resistant uropathogens. Jundishapur J. Microbiol. 9, e18952 (2016).

  122. 122.

    Shim, Y. H., Lee, S. J. & Lee, J. W. Antimicrobial activity of lactobacillus strains against uropathogens. Pediatr. Int. 58, 1009–1013 (2016).

  123. 123.

    Aroutcheva, A. et al. Defense factors of vaginal lactobacilli. Am. J. Obstetr. Gynecol. 185, 375–379 (2001).

  124. 124.

    Atassi, F. & Servin, A. L. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathogens. FEMS Microbiol. Lett. 304, 29–38 (2010).

  125. 125.

    Alakomi, H. L. et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl. Environ. Microbiol. 66, 2001–2005 (2000).

  126. 126.

    Amdekar, S., Singh, V. & Singh, D. D. Probiotic therapy: immunomodulating approach toward urinary tract infection. Curr. Microbiol. 63, 484–490 (2011).

  127. 127.

    Karlsson, M., Scherbak, N., Khalaf, H., Olsson, P. E. & Jass, J. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-κB activity in Escherichia coli-stimulated urinary bladder cells. FEMS Immunol. Med. Microbiol. 66, 147–156 (2012).

  128. 128.

    Fettweis, J. M. et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology 160, 2272–2282 (2014).

  129. 129.

    Baerheim, A., Larsen, E. & Digranes, A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care 12, 239–243 (1994).

  130. 130.

    Colodner, R., Edelstein, H., Chazan, B. & Raz, R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr. Med. Assoc. J. 5, 767–769 (2003).

  131. 131.

    Reid, G., Millsap, K. & Bruce, A. W. Implantation of Lactobacillus casei var rhamnosus into vagina. Lancet 344, 1229 (1994).

  132. 132.

    Morelli, L., Zonenenschain, D., Del Piano, M. & Cognein, P. Utilization of the intestinal tract as a delivery system for urogenital probiotics. J. Clin. Gastroenterol. 38, S107–S110 (2004).

  133. 133.

    Cribby, S., Taylor, M. & Reid, G. Vaginal microbiota and the use of probiotics. Interdiscip. Perspect. Infect. Dis. 2008, 256490 (2008).

  134. 134.

    Mezzasalma, V. et al. Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study. Arch. Gynecol. Obstetr. 295, 163–172 (2017).

  135. 135.

    Reid, G. et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. Microbiol. 35, 131–134 (2003).

  136. 136.

    Beerepoot, M. A. et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch. Intern. Med. 172, 704–712 (2012).

  137. 137.

    Lee, S. J., Shim, Y. H., Cho, S. J. & Lee, J. W. Probiotics prophylaxis in children with persistent primary vesicoureteral reflux. Pediatr. Nephrol. 22, 1315–1320 (2007).

  138. 138.

    Mohseni, M. J. et al. Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children. Iranian J. Pediatr. 23, 430–438 (2013).

  139. 139.

    Reid, G., Bruce, A. W. & Taylor, M. Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin. Ther. 14, 11–16 (1992).

  140. 140.

    Stapleton, A. E. et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 52, 1212–1217 (2011).

  141. 141.

    Schwenger, E. M., Tejani, A. M. & Loewen, P. S. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst. Rev. 12, CD008772 (2015).

  142. 142.

    Grin, P. M., Kowalewska, P. M., Alhazzan, W. & Fox-Robichaud, A. E. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can. J. Urol. 20, 6607–6614 (2013).

  143. 143.

    Davis, J. A. & Freeze, H. H. Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse. Biochim. Biophys. Acta 1528, 116–126 (2001).

  144. 144.

    Fronzes, R., Remaut, H. & Waksman, G. Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria. EMBO J. 27, 2271–2280 (2008).

  145. 145.

    Choudhury, D. et al. X-Ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 285, 1061–1066 (1999).

  146. 146.

    Zhou, G. et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci. 114, 4095–4103 (2001).

  147. 147.

    Pak, J., Pu, Y., Zhang, Z. T., Hasty, D. L. & Wu, X. R. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J. Biol. Chem. 276, 9924–9930 (2001).

  148. 148.

    Eto, D. S., Jones, T. A., Sundsbak, J. L. & Mulvey, M. A. Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog. 3, e100 (2007).

  149. 149.

    Mydock-McGrane, L. K., Cusumano, Z. T. & Janetka, J. W. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn’s disease. Expert Opin. Ther. Patents 26, 175–197 (2016).

  150. 150.

    Michaels, E. K., Chmiel, J. S., Plotkin, B. J. & Schaeffer, A. J. Effect of D-mannose and D-glucose on Escherichia coli bacteriuria in rats. Urol. Res. 11, 97–102 (1983).

  151. 151.

    Schaeffer, A. J., Chmiel, J. S., Duncan, J. L. & Falkowski, W. S. Mannose-sensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections. J. Urol. 131, 906–910 (1984).

  152. 152.

    Wellens, A. et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLOS ONE 3, e2040 (2008).

  153. 153.

    Cusumano, C. K. et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl Med. 3, 109ra115 (2011).

  154. 154.

    Spaulding, C. N. et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 546, 528–532 (2017).

  155. 155.

    Mydock-McGrane, L. K., Hannan, T. J. & Janetka, J. W. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease. Expert Opin. Drug Discov. 12, 711–731 (2017).

  156. 156.

    Kranjcec, B., Papes, D. & Altarac, S. D-Mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J. Urol. 32, 79–84 (2014).

  157. 157.

    Phe, V. et al. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol. Urodyn. 36, 1770–1775 (2017).

  158. 158.

    Vicariotto, F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. J. Clin. Gastroenterol. 48, S96–S101 (2014).

  159. 159.

    Naves, P. et al. Effects of human serum albumin, ibuprofen and N-acetyl-L-cysteine against biofilm formation by pathogenic Escherichia coli strains. J. Hosp. Infect. 76, 165–170 (2010).

  160. 160.

    Palleschi, G. et al. Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation. Arch. Ital. Urol. Androl. 89, 45–50 (2017).

  161. 161.

    Hamilton-Miller, J. M. & Brumfitt, W. Methenamine and its salts as urinary tract antiseptics: variables affecting the antibacterial activity of formaldehyde, mandelic acid, and hippuric acid in vitro. Invest. Urol. 14, 287–291 (1977).

  162. 162.

    Neely, W. B. Action of formaldehyde on microorganisms. III. Bactericidal action of sublethal concentrations of formaldehyde on aerobacter aerogenes. J. Bacteriol. 86, 445–448 (1963).

  163. 163.

    Musher, D. M. & Griffith, D. P. Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect. Antimicrob. Agents Chemother. 6, 708–711 (1974).

  164. 164.

    Lee, B. S., Bhuta, T., Simpson, J. M. & Craig, J. C. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst. Rev. 10, CD003265 (2012).

  165. 165.

    Nahata, M. C., Cummins, B. A., McLeod, D. C. & Butler, R. Predictability of methenamine efficacy based on type of urinary pathogen and pH. J. Am. Geriatr. Soc. 29, 236–239 (1981).

  166. 166.

    Nahata, M. C., Cummins, B. A., McLeod, D. C., Schondelmeyer, S. W. & Butler, R. Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. Eur. J. Clin. Pharmacol. 22, 281–284 (1982).

  167. 167.

    Sander, S. & Jakobsen, A. Jr. [Preventive Hiprex in urinary tract operations]. Tidsskr. Nor. Laegeforen. 96, 167–169 (1976).

  168. 168.

    Thomlinson, J., Williams, J. D. & Cope, E. Persistence of bacteriuria following gynaecological surgery: a trial of methenamine hippurate. Br. J. Urol. 40, 479–482 (1968).

  169. 169.

    ISRCTN registry. Alternatives to prophylactic antibiotics for the treatment of recurrent urinary tract infection in women. BMC (2016).

  170. 170.

    Mulvey, M. A., Schilling, J. D., Martinez, J. J. & Hultgren, S. J. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl Acad. Sci. USA 97, 8829–8835 (2000).

  171. 171.

    Teng, J., Wang, Z. Y., Jarrard, D. F. & Bjorling, D. E. Roles of estrogen receptor α and β in modulating urothelial cell proliferation. Endocr. Relat. Cancer 15, 351–364 (2008).

  172. 172.

    Simpson, E. R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 86, 225–230 (2003).

  173. 173.

    Raz, R. Hormone replacement therapy or prophylaxis in post-menopausal women with urinary tract infection. J. Infect. Dis. 183, 74–76 (2001).

  174. 174.

    Marshburn, P. B. & Carr, B. R. Hormone replacement therapy. Protection against the consequences of menopause. Postgrad. Med. 92, 145–148, 151–142, 157–149 (1992).

  175. 175.

    Luthje, P., Hirschberg, A. L. & Brauner, A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 77, 32–36 (2014).

  176. 176.

    Robinson, D. & Cardozo, L. Oestrogens and the lower urinary tract. BJOG 111 (Suppl. 1), 10–14 (2004).

  177. 177.

    Hannan, T. J., Hooton, T. M. & Hultgren, S. J. Estrogen and recurrent UTI: what are the facts? Sci. Transl Med. 5, 190fs123 (2013).

  178. 178.

    Mirmonsef, P. et al. Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause 22, 702–709 (2015).

  179. 179.

    Miller, L. et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstetr. Gynecol. 96, 431–439 (2000).

  180. 180.

    Raz, R. & Stamm, W. E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329, 753–756 (1993).

  181. 181.

    Chromek, M. et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12, 636–641 (2006).

  182. 182.

    Luthje, P. et al. Estrogen supports urothelial defense mechanisms. Sci. Transl Med. 5, 190ra180 (2013).

  183. 183.

    Stern, J. A., Hsieh, Y. C. & Schaeffer, A. J. Residual urine in an elderly female population: novel implications for oral estrogen replacement and impact on recurrent urinary tract infection. J. Urol. 171, 768–770 (2004).

  184. 184.

    Christiansen, C. & Riis, B. J. 17 β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J. Clin. Endocrinol. Metab. 71, 836–841 (1990).

  185. 185.

    Rossouw, J. E. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465–1477 (2007).

  186. 186.

    Cardozo, L., Lose, G., McClish, D. & Versi, E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet. Gynecol. Scand. 83, 892–897 (2004).

  187. 187.

    Brown, J. S. et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstetr. Gynecol. 98, 1045–1052 (2001).

  188. 188.

    Cardozo, L., Benness, C. & Abbott, D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br. J. Obstetr. Gynaecol. 105, 403–407 (1998).

  189. 189.

    Kirkengen, A. L. et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand. J. Prim. Health Care 10, 139–142 (1992).

  190. 190.

    Ouslander, J. G. et al. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J. Am. Geriatr. Soc. 49, 803–807 (2001).

  191. 191.

    Perrotta, C., Aznar, M., Mejia, R., Albert, X. & Ng, C. W. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst. Rev. 2, CD005131 (2008).

  192. 192.

    Raz, R. et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin. Infect. Dis. 36, 1362–1368 (2003).

  193. 193.

    Suckling, J., Lethaby, A. & Kennedy, R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 4, CD001500 (2006).

  194. 194.

    Eriksen, B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am. J. Obstetr. Gynecol. 180, 1072–1079 (1999).

  195. 195.

    Xu, R., Wu, Y. & Hu, Y. [Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi 36, 531–533 (2001).

  196. 196.

    Parsons, C. L., Boychuk, D., Jones, S., Hurst, R. & Callahan, H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J. Urol. 143, 139–142 (1990).

  197. 197.

    Parsons, C. L., Pollen, J. J., Anwar, H., Stauffer, C. & Schmidt, J. D. Antibacterial activity of bladder surface mucin duplicated in the rabbit bladder by exogenous glycosaminoglycan (sodium pentosanpolysulfate). Infect. Immun. 27, 876–881 (1980).

  198. 198.

    Parsons, C. L., Greenspan, C. & Mulholland, S. G. The primary antibacterial defense mechanism of the bladder. Invest. Urol. 13, 72–78 (1975).

  199. 199.

    Ruggieri, M. R., Hanno, P. M. & Levin, R. M. The effects of heparin on the adherence of five species of urinary tract pathogens to urinary bladder mucosa. Urol. Res. 12, 199–203 (1984).

  200. 200.

    Parsons, C. L. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 69, 9–16 (2007).

  201. 201.

    Cicione, A. et al. Restoring the glycosaminoglycans layer in recurrent cystitis: experimental and clinical foundations. Int. J. Urol. 21, 763–768 (2014).

  202. 202.

    Lee, D. G. et al. Preventive effects of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology 75, 949–954 (2010).

  203. 203.

    Hauser, P. J. et al. Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. J. Urol. 182, 2477–2482 (2009).

  204. 204.

    Yildiz, N. et al. Intravesical hyaluronic acid treatment improves bacterial cystitis and reduces cystitis-induced hypercontractility in rats. Int. J. Urol. 22, 598–603 (2015).

  205. 205.

    Tasdemir, S. et al. Intravesical hyaluronic acid and chondroitin sulfate alone and in combination for urinary tract infection: assessment of protective effects in a rat model. Int. J. Urol. 19, 1108–1112 (2012).

  206. 206.

    Nishimura, M. et al. Role of chondroitin sulfate-hyaluronan interactions in the viscoelastic properties of extracellular matrices and fluids. Biochim. Biophys. Acta 1380, 1–9 (1998).

  207. 207.

    Freissler, E., Meyer auf der Heyde, A., David, G., Meyer, T. F. & Dehio, C. Syndecan-1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells. Cell. Microbiol. 2, 69–82 (2000).

  208. 208.

    Laquerre, S. et al. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72, 6119–6130 (1998).

  209. 209.

    Constantinides, C. et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 93, 1262–1266 (2004).

  210. 210.

    Lipovac, M. et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int. J. Gynaecol. Obstetr. 96, 192–195 (2007).

  211. 211.

    Damiano, R. et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur. Urol. 59, 645–651 (2011).

  212. 212.

    De Vita, D. & Giordano, S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int. Urogynecol J. 23, 1707–1713 (2012).

  213. 213.

    Cicione, A. et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can. Urol. Assoc. J. 8, E721–E727 (2014).

  214. 214.

    Gugliotta, G. et al. Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control analysis. Taiwan J. Obstet. Gynecol. 54, 537–540 (2015).

  215. 215.

    Torella, M. et al. Intravesical therapy in recurrent cystitis: a multi-center experience. J. Infect. Chemother. 19, 920–925 (2013).

  216. 216.

    Ciani, O. et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open 6, e009669 (2016).

  217. 217.

    De Vita, D., Antell, H. & Giordano, S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis. Int. Urogynecol J. 24, 545–552 (2013).

  218. 218.

    Chan, C. Y., St John, A. L. & Abraham, S. N. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38, 349–359 (2013).

  219. 219.

    Brumbaugh, A. R. & Mobley, H. L. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev. Vaccines 11, 663–676 (2012).

  220. 220.

    Schmidhammer, S. et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60, 521–526 (2002).

  221. 221.

    Van Pham, T., Kreis, B., Corradin-Betz, S., Bauer, J. & Mauel, J. Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J. Biol. Response Mod. 9, 231–240 (1990).

  222. 222.

    Ha, U. S. & Cho, Y. H. Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. Int. J. Antimicrob. Agents 31, S63–S67 (2008).

  223. 223.

    Huber, M., Baier, W., Serr, A. & Bessler, W. G. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int. J. Immunopharmacol. 22, 57–68 (2000).

  224. 224.

    Lee, S. J., Kim, S. W., Cho, Y. H. & Yoon, M. S. Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis. World J. Urol. 24, 33–38 (2006).

  225. 225.

    Wagenlehner, F. M. et al. A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol. Intern. 95, 167–176 (2015).

  226. 226.

    Naber, K. G., Cho, Y. H., Matsumoto, T. & Schaeffer, A. J. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int. J. Antimicrob. Agents 33, 111–119 (2009).

  227. 227.

    Bonkat, G. et al. European Association of Urology Guidelines on urological infections. EAU (2018).

  228. 228.

    Das, P. Vaginal vaccine for recurrent urinary-tract infections. Lancet Infect. Dis. 2, 68 (2002).

  229. 229.

    Hopkins, W. J., Elkahwaji, J., Beierle, L. M., Leverson, G. E. & Uehling, D. T. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J. Urol. 177, 1349–1353 (2007).

  230. 230.

    Uehling, D. T., Hopkins, W. J., Elkahwaji, J. E., Schmidt, D. M. & Leverson, G. E. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J. Urol. 170, 867–869 (2003).

  231. 231.

    Benito-Villalvilla, C. et al. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 10, 924–935 (2017).

  232. 232.

    Lorenzo-Gomez, M. F. et al. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Frontiers Cell. Infect. Microbiol. 5, 50 (2015).

  233. 233.

    Yang, B. & Foley, S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int. 121, 289–292 (2018).

  234. 234.

    Lorenzo-Gomez, M. F. et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int. Urogynecol J. 24, 127–134 (2013).

  235. 235.

    US National Library of Medicine. (2018).

  236. 236.

    Marinova, S. et al. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int. J. Immunopathol. Pharmacol. 18, 457–473 (2005).

  237. 237.

    Langermann, S. et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181, 774–778 (2000).

  238. 238.

    Dupuis, M. et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 186, 18–27 (1998).

  239. 239.

    Asadi Karam, M. R., Oloomi, M., Mahdavi, M., Habibi, M. & Bouzari, S. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31, 1210–1216 (2013).

  240. 240.

    Roberts, J. A. et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J. Urol. 171, 1682–1685 (2004).

  241. 241.

    Goluszko, P. et al. Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin. Infect. Immun. 73, 627–631 (2005).

  242. 242.

    Flores-Mireles, A. L., Pinkner, J. S., Caparon, M. G. & Hultgren, S. J. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci. Transl Med. 6, 254ra127 (2014).

  243. 243.

    Brumbaugh, A. R., Smith, S. N. & Mobley, H. L. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect. Immun. 81, 3309–3316 (2013).

  244. 244.

    van den Dobbelsteen, G. P. et al. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine 34, 4152–4160 (2016).

  245. 245.

    Huttner, A. et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect. Dis. 17, 528–537 (2017).

  246. 246.

    Darouiche, R. O. et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology 78, 341–346 (2011).

  247. 247.

    Sunden, F., Hakansson, L., Ljunggren, E. & Wullt, B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 184, 179–185 (2010).

  248. 248.

    Koves, B. et al. Rare emergence of symptoms during long-term asymptomatic Escherichia coli 83972 carriage without an altered virulence factor repertoire. J. Urol. 191, 519–528 (2014).

Download references


Reviewer information

Nature Reviews Urology thanks T. J. Hannan, F. Wagenlehner and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

N.S., A.G., R.Z., A.S. and S.M. researched data for the article. S.M. made substantial contributions to discussions of content. All authors wrote the manuscript, and S.M. reviewed and edited the manuscript before submission.

Correspondence to Sachin Malde.

Ethics declarations

Competing interests

N.S., A.G. and R.Z. declare no competing interests. A.S. has received an unrestricted educational grant, is an adviser to and has received speaker fees from Allergan Ltd. and has received monies from Medtronic for promotional purposes. S.M. has received monies from Medtronic for promotional purposes.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1: Pathogenesis of urinary tract infection.
Fig. 2: Mechanisms of antimicrobial resistance by mobile genetic elements.
Fig. 3: Mechanisms of action of cranberry components in prevention of urinary tract infection.
Fig. 4: A-type and B-type linkages of proanthocyanidins.
Fig. 5: Mechanisms of action of lactobacilli in urinary tract infection prevention.
Fig. 6: Type 1 pili of Escherichia coli and the uroplakin 1a receptor.
Fig. 7: d-Mannose prevents binding of bacteria to urothelial cells.
Fig. 8: Chemical structure of heptyl-α-d-mannose.
Fig. 9: Structure of the glycosaminoglygan layer of the bladder wall.
Fig. 10: Nonantibiotic interventions for urinary tract infection.